Clinical Trials Logo

Circulating Tumor Cell clinical trials

View clinical trials related to Circulating Tumor Cell.

Filter by:

NCT ID: NCT03481101 Recruiting - Clinical trials for Non Small Cell Lung Cancer

WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC

WHENII
Start date: February 28, 2018
Phase: N/A
Study type: Interventional

Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.

NCT ID: NCT03479099 Completed - Clinical trials for Circulating Tumor Cell

Liquid Biopsy in Lung Cancer

Start date: March 12, 2018
Phase:
Study type: Observational

The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.

NCT ID: NCT03436329 Active, not recruiting - Lung Cancer Clinical Trials

Reduced Dissemination of Tumor Cells With Primary Ligation of the Vein in Patients With Lung Cancer

Start date: December 1, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the impact of the sequence of vessel interruption in lung cancer patients on tumor cell spread and patient survival by using peripheral blood circulating tumor cells.

NCT ID: NCT03337347 Completed - Colorectal Cancer Clinical Trials

Clinical Significance of Detecting CEA and CK20 mRNA-positive Cells in Colorectal Cancer Patients

Start date: January 1, 2004
Phase: N/A
Study type: Interventional

To determine whether the presence of circulating/disseminated tumor cells (CTCs/DTCs) in the blood and bone marrow of colorectal cancer (CRC) patients with localized disease is a negative prognostic factor, and to find correlations with other clinical/pathological disease characteristics.

NCT ID: NCT03295591 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Circulating Tumor Cells in mCRC for Liver Resection

Start date: June 1, 2017
Phase:
Study type: Observational

Resection of liver metastasis is potentially curative in patients with colorectal cancer bearing liver metastasis. However, early recurrence occurs in up to 30% in 3 months after liver resection. To optimize patient selection, the investigators propose to evaluate the the value of incorporating circulating tumor cells enumeration to clinical factors in a prospective study

NCT ID: NCT03071900 Recruiting - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

CTC Detection Rate in SCCHN With a in Vivo Device

Start date: June 22, 2016
Phase: N/A
Study type: Interventional

Detection rate and isolation yield of CTC is low in squamous cell carcinoma of head and neck (SCCHN) with in vitro approaches rely on limited sample volumes. In this study, we applied a new method, the CellCollector, which could capture CTC in vivo from peripheral blood.

NCT ID: NCT03050866 Active, not recruiting - Clinical trials for Metastatic Prostate Cancer

Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

CABA-V7
Start date: February 21, 2017
Phase: Phase 2
Study type: Interventional

After failure on docetaxel, which has been the standard first line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), several treatment options are currently available. In retrospective studies, resistance has been described to two of the treatment options, enzalutamide and abiraterone, when a splice variant of the Androgen Receptor (AR-V7) is present on circulating tumor cells (CTCs). The investigators hypothesize that patients with AR-V7 positive CTCs do have a meaningful response to cabazitaxel.

NCT ID: NCT02032368 Completed - Clinical trials for Hepatocellular Carcinoma

Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence

Start date: July 2010
Phase: N/A
Study type: Interventional

Circulating tumour cell (CTC) count could reflect the effect of postoperative transarterial chemoembolization (TACE) on hepatocellular carcinoma (HCC) recurrence.